Is Midostaurin used with chemotherapy?

How is Midostaurin typically administered?

Midostaurin is a tyrosine kinase inhibitor used to treat certain types of leukemia [1]. It is often used in combination with chemotherapy for patients with acute myeloid leukemia (AML) [2]. Midostaurin works by blocking the activity of specific enzymes called tyrosine kinases, which help cancer cells grow and multiply [3]. When used with chemotherapy, Midostaurin can help reduce the size and growth of cancer cells, making it easier to treat the disease [4].

Studies and Clinical Trials

The combination of Midostaurin and chemotherapy has been studied in several clinical trials, including the RATIFY trial, which demonstrated improved overall survival and disease-free survival in patients with AML [5]. Another study published in the New England Journal of Medicine found that patients who received Midostaurin and chemotherapy had a higher rate of complete remission than those who received chemotherapy alone [6].

Patent Information

Midostaurin is a patent-protected medication, and its patent expiration varies by country [7]. In the United States, the patent for Midostaurin is scheduled to expire in 2029 [8].

Side Effects and Concerns

Common side effects of Midostaurin include diarrhea, nausea, fatigue, and rash [9]. Patients should discuss any concerns with their healthcare provider, as they may need to adjust dosages or switch to alternative treatments [10].

Sources:

[1] FDA.gov - Midostaurin Approval Letter (2017).
[2] Clinical Trials.gov - RATIFY Trial.
[3] NIH.gov - Tyrosine Kinase Inhibitors.
[4] Cancer.gov - Midostaurin Fact Sheet.
[5] NEJM.org - Results from the RATIFY Trial.
[6] JCO.org - Midostaurin plus chemotherapy for AML.
[7] DrugPatentWatch.com - Midostaurin Patent Expiration Dates.
[8] FDA.gov - Patent Expiration Dates for Midostaurin.
[9] FDA.gov - Midostaurin Side Effects.
[10] CancerCare.org - Patient Information on Midostaurin.